Axogen, Inc. — Director's Dealing 2011

Oct 11, 2011

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AxoGen, Inc. (LECT)
CIK: 0000805928
Period of Report: 2011-09-30

Reporting Person: Hansen David K (See Remarks)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option	$0.25	2016-06-07	Common Stock (4752)		Direct
Stock Option	$0.25	2017-04-27	Common Stock (932)		Direct
Stock Option	$0.25	2017-12-06	Common Stock (634)		Direct
Stock Option	$0.25	2018-11-18	Common Stock (327)		Direct
Stock Option	$0.25	2020-06-09	Common Stock (3177)		Direct

Footnotes

F1: Pursuant to an Agreement and Plan of Merger, dated as of May 31, 2011, by and among LecTec Corporation ("LecTec"), Nerve Merger Sub Corp., a subsidiary of LecTec ("Merger Sub"), and AxoGen Corporation ("AC"), which the parties amended on June 30, 2011 and August 9, 2011 (as amended, the "Merger Agreement"), Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the "Merger"). The Merger was completed on September 30, 2011, and LecTec was renamed AxoGen, Inc. ("AxoGen"). In connection with the Merger, each option to purchase shares of AC common stock was converted to an option to purchase 0.03727336 of a share of AxoGen common stock.

F2: 100% of the options have vested.

F3: 555 options have vested, and 79 options are unvested.

F4: 204 options have vested, and 123 options are unvested.

F5: 794 options have vested, and 2,383 options are unvested.

F6: These options vest semi-annually over four years from the date of grant.